CIP2A

CIP2A
Identifiers
Aliases	CIP2A, C330027C09Rik, AA408511, AU018569, Cip2a, Kiaa1524, p90, KIAA1524, cell proliferation regulating inhibitor of protein phosphatase 2A, cellular inhibitor of PP2A, NOCIVA
External IDs	OMIM: 610643; MGI: 2146335; HomoloGene: 10842; GeneCards: CIP2A; OMA:CIP2A - orthologs
Gene location (Human)
Chr.	Chromosome 3 (human)
End	108,589,644 bp
Gene location (Mouse)
Chr.	Chromosome 16 (mouse)
End	48,840,072 bp
RNA expression pattern
	Top expressed in
	ventricular zone; ; secondary oocyte; ; gonad; ; testicle; ; ganglionic eminence; ; buccal mucosa cell; ; bone marrow cells; ; appendix; ; stromal cell of endometrium; ; rectum;
	Top expressed in
	genital tubercle; ; tail of embryo; ; ventricular zone; ; primitive streak; ; abdominal wall; ; cumulus cell; ; zygote; ; secondary oocyte; ; epiblast; ; dermis;
	More reference expression data
	; ; ; ;
	More reference expression data
Gene ontology
Molecular function	protein binding; cadherin binding; protein homodimerization activity;
Cellular component	integral component of membrane; plasma membrane; membrane; cytoplasm; cytosol;
Biological process	positive regulation of neural precursor cell proliferation; spermatogenesis;
	Sources:Amigo / QuickGO
Orthologs
	57650
	224171
	ENSG00000163507
	ENSMUSG00000033031
	Q8TCG1
	Q8BWY9
	NM_020890
	NM_172616
	NP_065941
	NP_766204
	Wikidata
View/Edit Human	View/Edit Mouse

Protein CIP2A also known as cancerous inhibitor of PP2A (CIP2A) is a protein that in humans is encoded by the KIAA1524 gene.

CIP2A is a regulatory protein involved in the inhibition of the serine-threonine phosphatase activity of Protein phosphatase 2A (PP2A). PP2A is a trimeric enzyme composed of a catalytic C-subunit, a scaffolding A-subunit, and various regulatory B-subunits, which collectively dephosphorylate a vast majority of cellular serine/threonine phosphorylated proteins, including many involved in cancer progression. CIP2A has been shown to regulate phosphorylation and activity of numerous oncoproteins, promoting malignant cell growth and tumorigenesis in various human cancers. High expression levels of CIP2A have been observed in multiple cancer types, such as head and neck cancer, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung cancer, correlating with poor patient prognosis and disease aggressivity. Additionally, CIP2A is implicated in resistance to cancer treatments, such as imatinib in chronic myeloid leukemia.